Courtagen Life Sciences
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $6.6m | Early VC | |
N/A | $7.6m | Early VC | |
N/A | $9.5m | Early VC | |
N/A | $7.0m | Early VC | |
$8.0m | Series B | ||
N/A | N/A | Seed | |
N/A | $6.3m | Early VC | |
$20.0m | Growth Equity VC | ||
Total Funding | $65.0m |
Related Content
Recent News about Courtagen Life Sciences
EditCourtagen Life Sciences, Inc. specializes in providing advanced genetic testing solutions aimed at personalized medicine. The company primarily serves healthcare providers, patients, and researchers by offering comprehensive diagnostic services that focus on neurological and metabolic disorders. Operating within the biotechnology and healthcare sectors, Courtagen leverages cutting-edge genomic technologies to deliver precise and actionable insights for patient care. The business model revolves around offering specialized genetic tests that are ordered by healthcare professionals to diagnose and manage complex medical conditions. Revenue is generated through the sale of these diagnostic tests, which are often covered by insurance providers. Courtagen's market includes hospitals, clinics, and research institutions that require high-quality genetic data to inform treatment plans and advance medical research. The company stands out by providing detailed reports that help in the diagnosis and treatment of rare and complex diseases, thereby improving patient outcomes.
Keywords: genetic testing, personalized medicine, neurological disorders, metabolic disorders, healthcare providers, biotechnology, genomic technologies, diagnostic services, patient care, medical research.